Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Lancet (London, England)|November 29, 2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyMarianne E Pavel, John D Hainsworth, Eric Baudin, et al.Endocrine-Related Cancer|January 12, 2026
Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)Jonathan R Strosberg, Tyler Zemla, Susan Geyer, et al.The New England Journal of Medicine|July 12, 2014
Lanreotide in metastatic enteropancreatic neuroendocrine tumorsMartyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.Pancreas|March 18, 2014
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experienceEbrahim S Delpassand, Amin Samarghandi, Sara Zamanian, et al.Endocrine-Related Cancer|January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension studyMartyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.Anti-Cancer Drugs|January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumorsTal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518James C Yao, Katherine A Guthrie, Cesar Moran, et al.World Journal of Gastroenterology|March 6, 2015
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumorsJonathan R Strosberg, George A Fisher, Al B Benson, et al.Pancreas|September 29, 2020
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine TumorsJennifer R Eads, Diane Reidy-Lagunes, Heloisa P Soares, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are ImplementedJeremie Calais, Johannes Czernin, Matthias Eiber, et al.Pageof 5